Cargando…
Evaluation of Bioequivalency and Pharmacokinetic Parameters for Two Formulations of Glimepiride 1-mg in Chinese Subjects
PURPOSE: Glimepiride, an FDA-approved oral hypoglycemic drug, is a long-acting sulfonylurea (SU), used for treating type 2 diabetes. The study aimed to evaluate the bioequivalence and safety profiles of two different formulations of glimepiride 1 mg from two different manufactures in healthy Chinese...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7351633/ https://www.ncbi.nlm.nih.gov/pubmed/32753845 http://dx.doi.org/10.2147/DDDT.S249355 |
_version_ | 1783557475765583872 |
---|---|
author | Ju, Gehang Yan, Keyu Xu, Youwei Chen, Shilin Zheng, Zhonghui Qiu, Wen |
author_facet | Ju, Gehang Yan, Keyu Xu, Youwei Chen, Shilin Zheng, Zhonghui Qiu, Wen |
author_sort | Ju, Gehang |
collection | PubMed |
description | PURPOSE: Glimepiride, an FDA-approved oral hypoglycemic drug, is a long-acting sulfonylurea (SU), used for treating type 2 diabetes. The study aimed to evaluate the bioequivalence and safety profiles of two different formulations of glimepiride 1 mg from two different manufactures in healthy Chinese subjects in the fasting and fed state in order to acquire adequate pharmacokinetic evidence for registration approval of the test formulation. PATIENTS AND METHODS: This study is an open-label, two-period, two-sequence, randomized, two-way crossover pharmacokinetic study in healthy Chinese subjects in the fasting and fed state. Seventy-two subjects were randomly assigned to the fasting group and the fed group (n=36 each). We collected blood samples, 24-h post drug administration. The plasma concentration of glimepiride was assessed using HPLC coupled with mass spectrometry. The following parameters were evaluated: AUC(0-inf), AUC(0-last), C(max), t(1⁄2), T(max), and λ(z). Safety was determined based on the occurrence of adverse events (AEs) and laboratory examinations (biochemistry, hematology, and urinalysis) throughout the entire study period. RESULTS: The geometric mean ratios (GMR) amongst the two glimepiride formulations for the primary pharmacokinetic parameters, ie, AUC(0-inf), AUC(0-last), and C(max) as well as the corresponding 90% CIs, were all within the range of 80.00–125.00% in the fasting and fed state. The safety profile for both treatments was comparable. CONCLUSION: PK analysis revealed that the test and reference formulations of glimepiride were bioequivalent and well tolerated in healthy Chinese subjects. Chinese Clinical Trials Registry identifier: CTR20171121. CLINICAL TRIAL REGISTRATION NUMBER: CTR20171121. |
format | Online Article Text |
id | pubmed-7351633 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-73516332020-08-03 Evaluation of Bioequivalency and Pharmacokinetic Parameters for Two Formulations of Glimepiride 1-mg in Chinese Subjects Ju, Gehang Yan, Keyu Xu, Youwei Chen, Shilin Zheng, Zhonghui Qiu, Wen Drug Des Devel Ther Clinical Trial Report PURPOSE: Glimepiride, an FDA-approved oral hypoglycemic drug, is a long-acting sulfonylurea (SU), used for treating type 2 diabetes. The study aimed to evaluate the bioequivalence and safety profiles of two different formulations of glimepiride 1 mg from two different manufactures in healthy Chinese subjects in the fasting and fed state in order to acquire adequate pharmacokinetic evidence for registration approval of the test formulation. PATIENTS AND METHODS: This study is an open-label, two-period, two-sequence, randomized, two-way crossover pharmacokinetic study in healthy Chinese subjects in the fasting and fed state. Seventy-two subjects were randomly assigned to the fasting group and the fed group (n=36 each). We collected blood samples, 24-h post drug administration. The plasma concentration of glimepiride was assessed using HPLC coupled with mass spectrometry. The following parameters were evaluated: AUC(0-inf), AUC(0-last), C(max), t(1⁄2), T(max), and λ(z). Safety was determined based on the occurrence of adverse events (AEs) and laboratory examinations (biochemistry, hematology, and urinalysis) throughout the entire study period. RESULTS: The geometric mean ratios (GMR) amongst the two glimepiride formulations for the primary pharmacokinetic parameters, ie, AUC(0-inf), AUC(0-last), and C(max) as well as the corresponding 90% CIs, were all within the range of 80.00–125.00% in the fasting and fed state. The safety profile for both treatments was comparable. CONCLUSION: PK analysis revealed that the test and reference formulations of glimepiride were bioequivalent and well tolerated in healthy Chinese subjects. Chinese Clinical Trials Registry identifier: CTR20171121. CLINICAL TRIAL REGISTRATION NUMBER: CTR20171121. Dove 2020-07-06 /pmc/articles/PMC7351633/ /pubmed/32753845 http://dx.doi.org/10.2147/DDDT.S249355 Text en © 2020 Ju et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Clinical Trial Report Ju, Gehang Yan, Keyu Xu, Youwei Chen, Shilin Zheng, Zhonghui Qiu, Wen Evaluation of Bioequivalency and Pharmacokinetic Parameters for Two Formulations of Glimepiride 1-mg in Chinese Subjects |
title | Evaluation of Bioequivalency and Pharmacokinetic Parameters for Two Formulations of Glimepiride 1-mg in Chinese Subjects |
title_full | Evaluation of Bioequivalency and Pharmacokinetic Parameters for Two Formulations of Glimepiride 1-mg in Chinese Subjects |
title_fullStr | Evaluation of Bioequivalency and Pharmacokinetic Parameters for Two Formulations of Glimepiride 1-mg in Chinese Subjects |
title_full_unstemmed | Evaluation of Bioequivalency and Pharmacokinetic Parameters for Two Formulations of Glimepiride 1-mg in Chinese Subjects |
title_short | Evaluation of Bioequivalency and Pharmacokinetic Parameters for Two Formulations of Glimepiride 1-mg in Chinese Subjects |
title_sort | evaluation of bioequivalency and pharmacokinetic parameters for two formulations of glimepiride 1-mg in chinese subjects |
topic | Clinical Trial Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7351633/ https://www.ncbi.nlm.nih.gov/pubmed/32753845 http://dx.doi.org/10.2147/DDDT.S249355 |
work_keys_str_mv | AT jugehang evaluationofbioequivalencyandpharmacokineticparametersfortwoformulationsofglimepiride1mginchinesesubjects AT yankeyu evaluationofbioequivalencyandpharmacokineticparametersfortwoformulationsofglimepiride1mginchinesesubjects AT xuyouwei evaluationofbioequivalencyandpharmacokineticparametersfortwoformulationsofglimepiride1mginchinesesubjects AT chenshilin evaluationofbioequivalencyandpharmacokineticparametersfortwoformulationsofglimepiride1mginchinesesubjects AT zhengzhonghui evaluationofbioequivalencyandpharmacokineticparametersfortwoformulationsofglimepiride1mginchinesesubjects AT qiuwen evaluationofbioequivalencyandpharmacokineticparametersfortwoformulationsofglimepiride1mginchinesesubjects |